World Health Organization Sounds Concern Over Acute Lack of Obesity Jabs
Fewer than a tenth of individuals eligible to benefit from obesity jabs including Wegovy have access to them, states the World Health Organization as it releases its initial recommendations on the medications.
Considering more than one billion people worldwide now living with obesity, it is calling for broader and more equitable access to this class of drugs.
Based on forecasts, over two billion will be living with obesity by 2030 unless action is taken.
"Our new guidance affirms that excess weight is a lifelong illness that can be treated with holistic and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are major hurdles to broad access to the treatments that can aid individuals in losing substantial body mass, says the agency.
GLP-1 Therapy Supply Crisis
Despite the current most optimistic scenario, the production of such drugs would only suffice for around 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The recommendation calls on nations and manufacturers to expand access, through approaches like voluntary licensing.
Exclusive production rights on the active ingredient – the main component of the drug Wegovy – is set to lapse in multiple countries in 2026.
How Weight-Loss Injections Operate
These medications replicate a natural hormone to reduce digestion speed, reduce hunger and enhance feelings of fullness so people eat less.
Individuals commonly start to lose weight within a few weeks of beginning the regular doses.
Evidence suggests users may see weight return within a year of stopping the drug, as their normal appetite come back.
Being carrying excess weight raises your likelihood for experiencing health problems, including type 2 diabetes, heart disease, stroke, and some cancers.
Excess weight affects individuals in all nations and was associated with 3.7 million fatalities worldwide in 2024, according to the WHO.
